LinkedIn-button

Services

Vaccine
development
service

The bridge between discovery
and pilot-scale GMP biomanufacturing.
Intravacc offers a one-stop shop
for independent vaccine development,
from discovery to pilot production
to clinical studies.

LEARN MORE
LinkedIn-button

Discover
Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization of innovative vaccines against infectious diseases. With over 100 years of experience in vaccine development and optimization, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world.

LEARN MOREANNUAL REPORT 2020
LinkedIn-button

Latest News

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…

  • Avacc 3 has significant advantages over existing whooping cough vaccines
  • Second major OMV platform licensing agreement with pharmaceutical company
  • Over 24 million cases of whooping cough per year world-wide
Read more

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from Institut Pasteur

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur Bilthoven, the Netherlands, and Paris, France, 22 March 2022 – Intravacc, a world leader in translational research and development of preventive…

  • Data published in the prestigious journal ACS Central Science of the American Chemical Society
  • Preclinical and clinical batches complying with ICH guidelines and WHO recommendations
  • Phase I clinical study showed vaccine was safe and well tolerated
  • Phase II clinical studies ongoing in endemic countries
Read more

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine Bilthoven, the Netherlands, 5 January 2022 – Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today…

  • Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
  • No use of mRNA or vector technology
  • Better and direct immunization of mucosa against multiple corona viruses
  • Intravacc focuses on preclinical and process development research and GMP vaccine production
  • Financing of clinical trial study made possible in part by Dutch governmental body Top Consortium for Knowledge and Innovation (TKI)
Read more
LinkedIn-button

Career

Join our team!

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

YOUR CAREER?

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.